Maclear Project Euro Medical Group
- Written by
- Just P2P
- •
- Updated August 1, 2025
Score B
Euro Medical Group is a Bulgarian company founded in 2022, specializing in medical equipment distribution, pharmaceutical products, and clinical consulting services for private healthcare practices. The company has demonstrated rapid growth with a three-year revenue CAGR exceeding 700% and expanding operations to Romania and Greece.
The company seeks funding to execute three signed equipment supply contracts with private clinics. The funding will enable the acquisition of certified diagnostic and therapeutic equipment with expected gross profit margins of 25% and strengthen the company’s position as an integrated healthcare solutions provider.
Investment terms
Loan requested : 700,000€
Period : 14 months
Interest rate : 14.6%
Loan requested : 105,500 € (95,000 € in client prepayments and 10,500 € in internal funds)
The loan represents a strategic investment for this fast-growing company operating in the Bulgarian private medical sector valued at 480 M$. The company’s substantial contribution of 105,500 € demonstrates strong commitment and reduces risk exposure. The 14-month term and 14.6% interest rate appropriately reflect the projected growth trajectory from 602,000 € in revenue in 2024 to 1,407,000 € in 2026.
Risk metrics
Debt/Equity Ratio : 1.56 (Medium risk)
LTV (Loan to Value) : 79% (Medium risk)
Credit History Score : 8/10 (Good creditworthiness)
The debt-to-equity ratio of 1.56 falls within the medium risk category, indicating moderate leverage that is manageable for a growing company. The LTV of 79% sits within the medium risk range but approaches the upper limit, supported by diversified collateral valued at 998,900 € in total.
The good credit history score of 8/10 reflects consistent payment behavior and financial discipline, reinforced by the previous debt-free capital structure and systematic reinvestment of profits. These metrics suggest a balanced risk profile with adequate creditor protection despite some tensions on coverage ratios.
Business profile
Geographic Location : Bulgaria (EU member states)
Industry Sector : Medical supply and clinical consulting
Collateral Type : Company assets, personal vehicle, and medical equipment
Their strategic location offers competitive advantages through reduced operational costs, access to certified European manufacturers, and simplified EU regulatory frameworks. The sector benefits from EU-funded infrastructure modernization programs and growing private investments in outpatient diagnostics.
The collateral comprises revenue-generating medical equipment, essential logistics vehicles, and high-quality operational assets. The company overcame 2023 difficulties related to intermediary costs by establishing direct manufacturer relationships, enabling revenue to triple in 2024 and demonstrating strong adaptation capacity.
Strenghts / Weaknesses
Strenghts
- Strong financial performance (700%+ revenue CAGR)
- Signed contracts 1,072,000 € (guaranteed revenues)
- Diversified collateral 999 K€ providing 143% loan coverage
- Expert founder in medical procurement
- Historically debt-free capital structure
- Profit reinvestment for growth
- Access to certified EU manufacturers, regulatory compliance
- Cross-border market expansion
- Integrated service model (competitive differentiation)
Weaknesses
- Young company with limited operating history
- Strong concentration on Bulgarian sector
- High LTV approaching risk limits
- Leverage effect in medium risk category
- Exposure to sector regulatory changes
- Dependence on external financing for growth
Review Euro Medical Group
The B rating is justified by solid financial performance with 700%+ revenue growth, signed contracts providing 1,072,000 € visibility, and experienced leadership, which partially offset the company’s short operating history of 3 years since foundation.
While the 79% LTV and sector concentration constitute concerns, the 143% collateral coverage, previous debt-free structure, and adaptation capacity demonstrated during the 2023-2024 transition provide reasonable assurance that this medium-risk investment opportunity offers attractive growth potential.
